Tango Therapeutics (TNGX) Change in Accured Expenses (2020 - 2026)

Tango Therapeutics' Change in Accured Expenses history runs 7 years deep, the most recent figure standing at -$8.7 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 41.9% year-over-year to -$8.7 million; the TTM figure through Mar 2026 stood at -$1.5 million (up 56.76% YoY), while the FY2025 annual figure was $1.1 million, down 2.65% from the prior year.
• Change in Accured Expenses was -$8.7 million for Q1 2026 at Tango Therapeutics, down from $4.5 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $4.5 million in Q4 2025 to a low of -$8.7 million in Q1 2026.
• Historically, Change in Accured Expenses has averaged -$50117.6 across 5 years, with a median of $1.5 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Change in Accured Expenses soared 4985.71% in 2022, then slumped 4169.43% in 2023.
• A 5-year view of Change in Accured Expenses shows it stood at $1.8 million in 2022, then soared by 124.55% to $4.0 million in 2023, then tumbled by 62.7% to $1.5 million in 2024, then surged by 201.01% to $4.5 million in 2025, then slumped by 293.63% to -$8.7 million in 2026.
• The last three Change in Accured Expenses figures came in at -$8.7 million (Q1 2026), $4.5 million (Q4 2025), and $1.6 million (Q3 2025), per Business Quant data.